AI and Computational Modeling Approaches for Dose Optimisation During Drug Development
Reinvent Drug Development and Safety with AI
Reimagining Pharmacovigilance
Beyond Human Intuition
FROM ALGORITHMS TO BIOLOGY
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Datwyler Pharma Packaging
Senior Manager Global Scientific Affairs
Renaud Janssen PhD is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging He frequently presents on international conferences on subjects related to elastomeric and aluminiumplastic closures for pharmaceutical applications Renaud also serves on several standardisation and pharmacopoeia committees as well as on industry task forces
Articles
Neoteric Solvents: A Paradigm Shift in Pharmaceutical Industrial Processes
The use of solvents in pharmaceutical industrial processes such as crystallisation extraction formulation developments purification synthesis etc is an inevitable and even its usage helps to obtain the final pharmaceutical products in desirable quality In search of ideal solvent suitable to cover all the desirable quality of finished pharmaceuticals
Research Insights
Compositionally Aware Estimation of Cross-correlations for Microbiome Data
Sequencing data are ubiquitous in modern biology For example RNAseq data have been used to identify genes associated with clinical outcomes of cancer patients
Case Studies
Isolation Technology: Case Study
A customer active in the hormone production recently searched an appropriate solution for grinding material and clean packaging after the filtering and drying process The following requirements had to be met To provide a safe barrier between the operator and the active drug substance to provide both operator and product protect
Techno Trends
Aprea Therapeutics to Treat Myelodysplastic Syndromes
Aprea Therapeutics has launched a mutant p reactivating compound APR in combination with chemotherapy drug azacitidine for the treatment of Myelodysplastic Syndromes MDS in patients having a susceptible TP mutation
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Unknown Sources of Error in the Pharmaceutical Weighing Process
Thomas Caratsch has been the Head of Laboratory Division since December 2007 at the company's headquarters in Greifensee, Switzerland. Prior to joining the company, Caratsch held various management positions within the Hoffmann La Roche group in the U.S. and Switzerland, including General Manager of Roche Instrument Centre AG and Head of Disetronic Medical Systems AG. He began his career as a development engineer at Sodeco-Saia in Geneva.
Generative AI and the New Era of Personalized Medicine
Uddalak Das, PhD scholar at IISc Bengaluru, specializes in drug discovery and cancer immunotherapeutics. With 20+ publications, a patent, and collaborations with institutes like NCBS, JNU, and inStem, he advances green healthcare solutions. He is a member of AACR and EACR among others and has received multiple national fellowships and research grants.
Applying Human Factors Engineering to Generic Combination Products
Frauke Schuurkamp has 12 years of experience delivering HFE services to the medical and pharmaceutical industries. Schuurkamp conducts HFE workshops, advises on HFE strategies, leads research and analysis activities and develops key deliverables to support FDA and international regulatory submissions. Schuurkamp holds a bachelor’s degree in applied psychology and a master’s degree in human factors psychology.
Lisanne de Vogel has 7+ years of experience delivering HFE services to the medical device and pharmaceutical industries. Lisanne leads and oversees human factors research activities, such as usability testing, and helps clients develop key HFE documents for their (international) regulatory submissions, as well as advising them on how to apply HFE during product development to meet regulators' expectations. She holds a bachelor’s degree in Communication Science and a master’s degree in Applied Cognitive Psychology.
How Big Data is Transforming Clinical Trials in Asia
I’m Atharva, a content writer currently at Consegic Business Intelligence. With over 3 years of professional experience, I've specialised as a ghostwriter for prominent companies and industry publications, exploring various topics.
Untapped Opportunities in Southeast Asia
Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.
press releasesRead more...
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
Roche announced today new twoyear data from the Phase IIIbIV SALWEEN study of Vabysmo faricimab presented at the th AsiaPacific Vitreoretina Society APVRS Congress in Australia
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
Simcere Zaiminga subsidiary of Simcere Pharmaceutical Group HK today announced that it has entered into an exclusive global licensing agreement with Roche for the development and commercialization
T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
TMAXIMUM PHARMACEUTICAL Inc TMAXIMUM today announced that its investigational allogeneic CART cell therapy MT has been granted Fast Track Designation FTD by the US Food and Drug Administration FDA for the treatment of recurrent glioblastoma
Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan in combination with pertuzumab has been approved in the European Union EU for the stline treatment of adult patients with unresectable or metastatic HERpositive breast cancer
RMIT and GonGlobal partner to replace IVF injections with inhaled medicines
RMIT University researchers are working with Melbourne company GonGlobal to develop an inhaled alternative to in vitro fertilisation IVF injections a change that could make treatment dramatically easier for patients
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Vertex Pharmaceuticals Incorporated Nasdaq VRTX today announced the successful completion of the acquisition of Crinetics Pharmaceuticals Inc Nasdaq CRNX a global pharmaceutical company focused
EventsRead more...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy
Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine
Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains
Cipla Enters into Agreement with SBP Group for HER2 bispecific ADC TQB2102
Cipla and Sino Biopharmaceutical SBP Group have entered into an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan also known as TQB a HERtargeted bispecific antibodydrug conjugate ADC being developed for the treatment of cancer
Jazz Pharmaceuticals Announces Approval of Ziihera Regimens for Advanced HER2-Positive Gastroesophageal Cancer
Jazz Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved two Ziihera zanidatamabhriibased treatment regimens for the firstline treatment of adults with unresectable
BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients
BioCryst Pharmaceuticals has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORLADEYO berotralstat for the prevention of hereditary angioedema HAE attacks in children aged to under years
Takeda Receives Approval for ORZEYFUL (oveporexton) to Treat Narcolepsy Type 1
Takeda has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORZEYFUL oveporexton for the treatment of narcolepsy type NT a form of narcolepsy associated with cataplexy in adults
